arrow
K

Kevin Haynes

case western reserve university
H指数:54
被引数:9,401

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine

基于真实世界数据网络的疫苗安全性监测快速循环分析框架:加强监测强生COVID-19疫苗的经验

VACCINE
IF3.5
2025-05-010
OAAI
Assessing Real-World Data From Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force

评估来自电子健康记录的真实数据以进行卫生技术评估: 适用性清单: ISPOR工作组的良好实践报告

2024-06-017
PRE
Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study
2023-04-016
OAAI
Real-World Evidence Comparing Vedolizumab and Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's Disease
2022-11-2611
PRE
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease

阿司匹林给药在心血管疾病中的比较效果

2021-05-27167
OA
Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease

美国2型糖尿病和动脉粥样硬化性心血管疾病参保患者循证治疗的差距

2021-01-1936
OAAI
PCORnet® 2020: current state, accomplishments, and future directions

PCORnet®2020: 当前状态、成就和未来方向

2021-01-01103
OAAI
Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the IMplementation of a randomized controlled trial to imProve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AFib)
2020-11-0118
OAAI
Computable Phenotype Implementation for a National, Multicenter Pragmatic Clinical Trial Lessons Learned From ADAPTABLE

从适应性强的经验教训中吸取的全国性、多中心、实用性临床试验的可计算表型实施

2020-06-0122
OAAI
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial

阿司匹林剂量的基本原理和设计-以患者为中心的试验评估益处和长期有效性 (适应性) 试验

2020-05-0168
OAAI
Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes
2017-07-3111
OAAI